Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study) | Zendy

Aleksander Maciąg | Zendy; Michał M. Farkowski | Zendy; Tomasz Chwyczko | Zendy; Maciej Bęćkowski | Zendy; Paweł Syska | Zendy; Ilona Kowalik | Zendy; Mariusz Pytkowski | Zendy; Jacek Woźniak | Zendy; Rafał Dąbrowski | Zendy; Hanna Szwed | Zendy

AI Assistant Blog Pricing

Open Access

Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study)

Author(s) -

Aleksander Maciąg,

Michał M. Farkowski,

Tomasz Chwyczko,

Maciej Bęćkowski,

Paweł Syska,

Ilona Kowalik,

Mariusz Pytkowski,

Jacek Woźniak,

Rafał Dąbrowski,

Hanna Szwed

Publication year - 2016

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/euw384

Subject(s) - medicine , atrial fibrillation , sinus rhythm , cardiology , anesthesia , atrial flutter , placebo , cardioversion , pathology , alternative medicine

The aim of the study was to assess the clinical efficacy of antazoline, a first-generation anti-histaminic agent, in the rapid conversion of paroxysmal non-valvular atrial fibrillation (AF) to sinus rhythm in patients without heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog